Company Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2000 |
| IPO Date | Feb 8, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Yuichi Iwaki M.D., Ph.D. |
Contact Details
Address: 4275 Executive Square, Suite 300 La Jolla, California 92037 United States | |
| Phone | 858-373-1500 |
| Website | medicinova.com |
Stock Details
| Ticker Symbol | MNOV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001226616 |
| CUSIP Number | 58468P206 |
| ISIN Number | US58468P2065 |
| Employer ID | 33-0927979 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Executive Director |
| Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. | Chief Medical Officer and Director |
| Jason J. Kruger CPA | Chief Financial Officer and Principal Financial Officer |
| Dr. David H. Crean M.B.A., Ph.D. | Chief Business Officer |
| John O'Neil CPA | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 10-K | Annual Report |
| Jan 19, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 19, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 19, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 19, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Aug 9, 2023 | 10-Q | Quarterly Report |
| Aug 7, 2023 | 8-K | Current Report |
| Jun 22, 2023 | 8-K | Current Report |